Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of Β-glucuronidase in tumors

Cancer Gene Therapy

Volumn 18, Issue 6, 2011, Pages 381-389

  Huang, P T ^a   Chen, K C ^a   Prijovich, Z M ^a   Cheng, T L ^b   Leu, Y L ^c   Roffler, S R ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

glucuronidase; adenovirus; cancer therapy; CPT 11; prodrug; SN 38G

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ADENOVIRUS VECTOR; BETA GLUCURONIDASE; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER CELL; CANCER CELL CULTURE; CELL KILLING; CELL MEMBRANE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BYSTANDER EFFECT; CAMPTOTHECIN; COMBINED MODALITY THERAPY; GENE THERAPY; GENETIC VECTORS; GLUCURONATES; GLUCURONIDASE; HUMANS; NEOPLASMS; PRODRUGS; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 79956116029     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.3     Document Type: Article

References (50)

1. Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M, Shapiro CL. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Ann Oncol 2008; 19: 1417-1422.
2. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
3. Nair J, de Stanchina E, Schwartz G. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res 2009; 15: 2022-2030.
4. Font A, Salazar R, Maurel J, Taron M, Ramirez J, Tabernero J et al. Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer Chemother Pharmacol 2008; 62: 1075-1083.
5. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a no¬vel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994; 17: 662-664. (Pubitemid 24186112)
6. Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxyl-esterase. Biochem Pharmacol 1996; 52: 1103-1111. (Pubitemid 26338269)
7. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intra-cellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187-4191.
8. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucu-ronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847-854. (Pubitemid 28096082)
9. Lokiec F, Canal P, Gay C, Chatelut E, Armand JP, Roche H et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 1995; 36: 79-82.
10. Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 1997; 3: 1261-1266. (Pubitemid 27362386)
11. Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998; 4: 2747-2754. (Pubitemid 28523501)
12. Rouits E, Charasson V, Petain A, Boisdron-Celle M, Delord JP, Fonck M et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008; 99: 1239-1245.
13. Niculescu-Duvaz I, Springer C. Introduction to the back-ground, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005; 30: 71-88. (Pubitemid 41411170)
14. Kojima A, Hackett NR, Ohwada A, Crystal RG. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest 1998; 101: 1789-1796. (Pubitemid 28198510)
15. Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC, Potter PM. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylester-ase. Cancer Res 2001; 61: 5078-5082. (Pubitemid 32681538)
16. Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM et al. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Br J Cancer 2001; 84: 550-557. (Pubitemid 32215885)
17. Prijovich ZM, Chen BM, Leu YL, Chern JW, Roffler SR. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. Br J Cancer 2002; 86: 1634-1638. (Pubitemid 34628119)
18. Takasuna K, Hagiwara T, HirohashiM, Kato M, Nomura M, Nagai E et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor campto-thecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56: 3752-3757. (Pubitemid 26272025)
19. Cheng TL, Chou WC, Chen BM, Chern JW, Roffler SR. Characterization of an antineoplastic glucuronide prodrug. Biochem Pharmacol 1999; 58: 325-328. (Pubitemid 29255951)
20. Weyel D, Sedlacek H, Muller R, Brusselbach S. Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther 2000; 7: 224-231. (Pubitemid 30113771)
21. Cheng TL, Roffler S. Membrane-tethered proteins for basic research, imaging, and therapy. Med Res Rev 2008; 28: 885-928.
22. Heine D, Muller R, Brusselbach S. Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy. Gene Ther 2001; 8: 1005-1010. (Pubitemid 32633377)
23. Chen KC, Cheng TL, Leu YL, Prijovich ZM, Chuang CH, Chen BM et al. Membrane-localized activation of glucu-ronide prodrugs by beta-glucuronidase enzymes. Cancer Gene Ther 2007; 14: 187-200. (Pubitemid 46106962)
24. Prijovich ZM, Chen KC, Roffler SR. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy. Mol Cancer Ther 2009; 8: 940-946.
25. Rots M, Curiel D, Gerritsen W, Haisma H. Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors. J Control Release 2003; 87(1-3): 159-165. (Pubitemid 36255453)
26. Huang XW, Lieber A, Tang ZY, Lawrence TS, Moyer MP, Zhang M. Gene expression in intrahepatic tumors through DNA recombination by a replication-activated adenovirus vector. Cancer Gene Ther 2004; 11: 450-456. (Pubitemid 38747376)
27. Glasgow J, Everts M, Curiel D. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006; 13: 830-844.
28. Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1984. Mol Ther 2009; 17: 1292-1299.
29. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997; 17: 353-360. (Pubitemid 127500840)
30. Marshall CJ, Franks LM, Carbonell AW. Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst 1977; 58: 1743-1751. (Pubitemid 8118752)
31. Roffler SR, Wang HE, Yu HM, Chang WD, Cheng CM, Lu YL et al. A membrane antibody receptor for noninvasive imaging of gene expression. Gene Ther 2006; 13: 412-420.
32. Shayakhmetov D, Papayannopoulou T, Stamatoyannopou-los G, Lieber A. Efficient gene transfer into human CD34 (+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567-2583. (Pubitemid 30117566)
33. Steinwaerder D, Carlson C, Otto D, Li Z, Ni S, Lieber A. Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nat Med 2001; 7: 240-243. (Pubitemid 32148493)
34. Xu F, Li S, Li X, Guo Y, Zou B, Xu R et al. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther 2009; 16: 723-730.
35. Fuchita M, Ardiani A, Zhao L, Serve K, Stoddard BL, Black ME. Bacterial cytosine deaminase mutants created by mole-cular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo. Cancer Res 2009; 69: 4791-4799.
36. Schepelmann S, Hallenbeck P, Ogilvie LM, Hedley D, Friedlos F, Martin J et al. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res 2005; 65: 5003-5008. (Pubitemid 40827305)
37. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7: 2182-2194. (Pubitemid 32751614)
38. D'Arpa P, Beardmore C, Liu L. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1990; 50: 6919-6924. (Pubitemid 20361091)
39. Su YC, Chuang KH, Wang YM, Cheng CM, Lin SR, Wang JY et al. Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored [beta]-glucuroni-dase. Gene Ther 2007; 14: 565-574.
40. Liao K, Chou W, Lo Y, Roffler S. Design of transgenes for efficient expression of active chimeric proteins on mamma-lian cells. Biotechnol Bioeng 2001; 73: 313-323. (Pubitemid 32390658)
41. Dachs G, Hunt M, Syddall S, Singleton D, Patterson A. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009; 14: 4517-4545.
42. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998; 58: 1195-1201. (Pubitemid 28183208)
43. Juan TY, Roffler SR, Hou HS, Huang SM, Chen KC, Leu YL et al. Antiangiogenesis targeting tumor microenviron-ment synergizes glucuronide prodrug antitumor activity. Clin Cancer Res 2009; 15: 4600-4611.
44. Tzou S, Roffler S, Chuang K, Yeh H, Kao C, Su Y et al. Micro-PET imaging of beta-glucuronidase activity by the hydrophobic conversion of a glucuronide probe. Radiology 2009; 252: 754-762.
45. Tobin PJ, Dodds HM, Clarke S, Schnitzler M, Rivory LP. The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours. Oncol Rep 2003; 10: 1977-1979.
46. Dodds HM, Tobin PJ, Stewart CF, Cheshire P, Hanna S, Houghton P et al. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. J Pharmacol Exp Ther 2002; 303: 649-655. (Pubitemid 35231237)
47. Chen KC, Wu CH, Chang CY, Lu WC, Tseng Q, Prijovich ZM et al. Directed evolution of a lysosomal enzyme with enhanced activity at neutral pH by mammalian cell-surface display. Chem Biol 2008; 15: 1277-1286. (Pubitemid 352841466)
48. Cheng C, Lu Y, Chuang K, Hung W, Shiea J, Su Y et al. Tumor-targeting prodrug-activating bacteria for cancer therapy. Cancer Gene Ther 2008; 15: 393-401. (Pubitemid 351693224)
49. Wierdl M, Tsurkan L, Hyatt J, Edwards C, Hatfield M, Morton C et al. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther 2008; 15: 183-192. (Pubitemid 351240667)
50. Danks MK, Yoon KJ, Bush RA, Remack JS, Wierdl M, Tsurkan L et al. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 2007; 67: 22-25. (Pubitemid 46142755)